阿拉丁(688179) - 2024 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit of between 120.8473 million and 128.7608 million CNY for 2024, an increase of 35.0183 million to 42.9317 million CNY, representing a year-on-year growth of 40.80% to 50.02%[4] - The net profit attributable to the parent company is projected to be between 103.7115 million and 110.2962 million CNY, an increase of 17.8824 million to 24.4671 million CNY, reflecting a year-on-year increase of 20.83% to 28.51%[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be between 102.0911 million and 108.6759 million CNY, an increase of 18.6425 million to 25.2272 million CNY, indicating a year-on-year growth of 22.34% to 30.23%[4] - The previous year's net profit attributable to the parent company was 85.8291 million CNY, with a basic earnings per share of 0.49 CNY[5] Factors Influencing Performance - The company attributes the expected performance growth to its diverse product offerings, continuous investment in new product development, and effective market promotion strategies[7] - The consolidation of the subsidiary Shanghai Yuan Ye Biotechnology Co., Ltd. from the second quarter is expected to contribute positively to financial metrics[7] Forecast Validity and Caution - The performance forecast has not been audited by a registered accountant, and the company has not identified any significant uncertainties affecting the accuracy of the forecast[8] - Investors are advised to note that the forecast data is preliminary and subject to change upon the release of the 2024 annual report[9]